MedWire News: Results from the CURRENT-OASIS 7 study suggest that neither a double-dose of clopidogrel in the first week, nor high-dose aspirin, after acute coronary syndrome (ACS) reduces the risk for cardiovascular (CV) events compared with standard doses of each drug in patients referred for invasive treatment.
